CRISPR Therapeutics AG
NASDAQ:CRSP
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
CH |
CRISPR Therapeutics AG
NASDAQ:CRSP
|
4.9B USD | -30.7 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.7B USD | 12.5 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.1B USD | 20.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 30.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108B USD | 23.2 | ||
AU |
CSL Ltd
ASX:CSL
|
135.9B AUD | 33.6 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.1B USD | 9.5 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.6B USD | -19.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -79.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 20.4 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 25.6 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.